Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

Neurobiology of Disease

Volumn 42, Issue 3, 2011, Pages 496-505

  Sandi, Chiranjeevi ^a   Pinto, Ricardo Mouro ^a,d   Al Mahdawi, Sahar ^a   Ezzatizadeh, Vahid ^a   Barnes, Glenn ^b   Jones, Steve ^b   Rusche, James R ^b   Gottesfeld, Joel M ^c   Pook, Mark A ^a  

^a BRUNEL UNIVERSITY   (United Kingdom)

^b REPLIGEN CORPORATION   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

FRDA, frataxin; Friedreich ataxia; HDAC inhibitor; Histone deacetylase inhibitor; Transgenic mouse model; Trinucleotide repeat

Indexed keywords

ACONITATE HYDRATASE; FRATAXIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MESSENGER RNA; N [6 (2 AMINO 4 FLUOROPHENYLAMINO) 6 OXYHEXYL] 4 METHYLBENZAMIDE; N [6 (2 AMINOPHENYLAMINO) 6 OXYHEXYL] 4 METHYLBENZAMIDE; N' (2 AMINOPHENYL) N7 4 TOLYLHEPTANEDIAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FRIEDREICH ATAXIA; FXN GENE; GENE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HISTONE ACETYLATION; LOCOMOTION; MOTOR COORDINATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY TESTING;

ACONITATE HYDRATASE; ANALYSIS OF VARIANCE; ANIMALS; BENZAMIDES; BLOTTING, WESTERN; BODY WEIGHT; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FRIEDREICH ATAXIA; HISTONE DEACETYLASE INHIBITORS; MICE; MOTOR ACTIVITY; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROTAROD PERFORMANCE TEST;

EID: 79954628287     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.02.016     Document Type: Article

References (44)

1. Acquaviva F., et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 2008, 7:360-365.
2. Al-Mahdawi S., et al. GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics 2004, 84:301-310.
3. Al-Mahdawi S., et al. GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics 2006, 88:580-590.
4. Al-Mahdawi S., et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet. 2008, 17:735-746.
5. Antos C.L., et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 2003, 278:28930-28937.
6. Bradley J.L., et al. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. Hum. Mol. Genet. 2000, 9:275-282.
7. Butler R., Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7:784-796.
8. Campuzano V., et al. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996, 271:1423-1427.
9. Campuzano V., et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Mol. Genet. 1997, 6:1771-1780.
10. Cang S., et al. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 2009, 2:22.
11. Chou C.J., et al. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem. 2008, 283:35402-35409.
12. Clark R.M., et al. The GAA triplet-repeat is unstable in the context of the human FXN locus and displays age-dependent expansions in cerebellum and DRG in a transgenic mouse model. Hum. Genet. 2007, 120:633-640.
13. Cossee M., et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum. Mol. Genet. 2000, 9:1219-1226.
14. De Biase I., et al. Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS ONE 2009, 4:e7914.
15. Drummond D.C., et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 2005, 45:495-528.
16. Garbes L., et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Hum. Mol. Genet. 2009, 18:3645-3658.
17. Gottesfeld J.M., Pandolfo M. Development of histone deacetylase inhibitors as therapeutics for neurological disease. Future Neurol. 2009, 4:775-784.
18. Grabczyk E., et al. A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res. 2007, 35:5351-5359.
19. Greene E., et al. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res. 2007, 35:3383-3390.
20. Hahnen E., et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. 2006, 98:193-202.
21. Herman D., et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2006, 2:551-558.
22. Hockly E., et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. U. S. A. 2003, 100:2041-2046.
23. Hutt, D.M., et al., 2010. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6, 25-33.
24. Kernochan L.E., et al. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 2005, 14:1171-1182.
25. Koeppen A.H., et al. The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol. 2007, 114:163-173.
26. Koeppen A.H., et al. The dorsal root ganglion in Friedreich's ataxia. Acta Neuropathol. 2009, 118:763-776.
27. Monneret C. Histone deacetylase inhibitors. Eur. J. Med. Chem. 2005, 40:1-13.
28. Pandolfo M., Pastore A. The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 2009, 256(Suppl 1):9-17.
29. Pook M.A., et al. Rescue of the Friedreich's ataxia knockout mouse by human YAC transgenesis. Neurogenetics 2001, 3:185-193.
30. Prince H.M., et al. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res. 2009, 15:3958-3969.
31. Puccio H., et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat. Genet. 2001, 27:181-186.
32. Rai M., et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 2008, 3:e1958.
33. Rai M., et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS ONE 2010, 5:e8825.
34. Reid G., et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005, 24:4894-4907.
35. Riessland M., et al. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. 2006, 120:101-110.
36. Rotig A., et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. 1997, 17:215-217.
37. Rufini A., et al. Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia. Hum. Mol. Genet. 2011, 20:1253-1261.
38. Saveliev A., et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature 2003, 422:909-913.
39. Schulz J.B., et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol. 2009, 5:222-234.
40. Simon D., et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J. Neurosci. 2004, 24:1987-1995.
41. Soragni E., et al. Long intronic GAA*TTC repeats induce epigenetic changes and reporter gene silencing in a molecular model of Friedreich ataxia. Nucleic Acids Res. 2008, 36:6056-6065.
42. Thomas E.A., et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. U. S. A. 2008, 105:15564-15569.
43. Wells R.D. DNA triplexes and Friedreich ataxia. FASEB J. 2008, 22:1625-1634.
44. Xu C., et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem. Biol. 2009, 16:980-989.